Compare · BIOC vs CI
BIOC vs CI
Side-by-side comparison of Biocept Inc. (BIOC) and The Cigna Group (CI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIOC and CI operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $73.81B, about 1623.1x BIOC ($45.5M).
- CI has hit the wire 7 times in the past 4 weeks while BIOC has been quiet.
- CI has more recent analyst coverage (25 ratings vs 0 for BIOC).
- Company
- Biocept Inc.
- The Cigna Group
- Price
- $0.41-20.43%
- $279.37-0.35%
- Market cap
- $45.5M
- $73.81B
- 1M return
- -
- -3.98%
- 1Y return
- -
- -6.93%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 0
- 7
- Recent ratings
- 0
- 25
Biocept Inc.
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. Its Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from circulating tumor DNA; and Target-Selector CTC and molecular platforms provide biomarker detection and monitoring capabilities. In addition, it offers laboratory services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians. Further, it is developing PCR-based assays for detecting the COVID-19 virus. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. It has a partnership with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Latest BIOC
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Why EngageSmart Shares Are Trading Higher By Around 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Biocept Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Why Netflix Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
- Why Nuvve Holding Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
Latest CI
- SEC Form 4 filed by Officer Holgerson Bryan
- Officer Jones Nicole S sold $748,516 worth of shares (2,677 units at $279.61) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 25,880 units (SEC Form 4)
- SEC Form 144 filed by The Cigna Group
- Officer Jones Nicole S exercised 15,346 shares at a strike of $192.02 and sold $5,369,584 worth of shares (19,436 units at $276.27) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 28,557 units (SEC Form 4)
- SEC Form 144 filed by The Cigna Group
- The Cigna Group downgraded by Jefferies with a new price target
- The Cigna Group downgraded by Raymond James with a new price target
- SEC Form 10-Q filed by The Cigna Group
- The Cigna Group filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- The Cigna Group Reports Strong Second Quarter 2026 Results, Raises 2026 Outlook